What is Stilla Technologies?
Founded in 2013 and headquartered in Villejuif, France, Stilla Technologies specializes in the development of next-generation genetic testing solutions. The company is best known for its flexible digital PCR (dPCR) platform, which provides researchers and clinicians with unprecedented sensitivity and precision in nucleic acid quantification. By focusing on the intersection of genomics and digital health, Stilla Technologies addresses critical unmet needs in biopharmaceutical drug development, gene editing, and molecular diagnostics. Its market position is characterized by a commitment to high-throughput, scalable laboratory equipment that empowers the life sciences industry to accelerate complex genetic research.
How much funding has Stilla Technologies raised?
Stilla Technologies has raised a total of $76.7M across 4 funding rounds:
Angel/Seed
$135K
Series A
$19.5M
Series B
$22M
Debt
$35M
Angel/Seed (2014): $135K with participation from Wilco
Series A (2018): $19.5M led by Idinvest Partners, Illumina Ventures, Kurma Partners, Paris Saclay Seeds, LBO France, and BNP Paribas D�veloppement
Series B (2020): $22M supported by BNP Paribas Développement, Idinvest Partners, Illumina Ventures, LBO France, Kurma Partners, Paris Saclay Seed Funds, and Tus-Holdings Co. , Ltd.
Debt (2021): $35.1M featuring Eurazeo, Casdin Capital, Kurma Partners, European Investment Bank, BNP Paribas Developpement, Illumina Ventures, TusPark Capital Management, and LBO France
Key Investors in Stilla Technologies
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, focused on building an ecosystem that translates investment into innovation to enhance human health.
Kurma Partners
Kurma Partners is a prominent player in funding healthcare and biotechnology ventures across Europe, specializing in transforming disruptive scientific discoveries into advanced medical solutions.
LBO France
LBO France is a leading investment fund with over 30 years of expertise in private equity and venture capital, focusing on innovative sectors like digital health to build international champions.
What's next for Stilla Technologies?
Looking ahead, the strategic deployment of $35.1M is expected to catalyze the international expansion of Stilla Technologies' commercial operations. The company is well-positioned to leverage its current capital base to enhance its R&D pipeline, focusing on the integration of artificial intelligence within its dPCR workflows to further streamline diagnostic accuracy. As the firm transitions into a more mature phase of its lifecycle, the focus will likely shift toward deepening its footprint in the North American and Asian markets, while simultaneously exploring new applications for its technology in liquid biopsy and oncology. The continued backing from specialized life science investors suggests a long-term commitment to establishing Stilla as a cornerstone of the global genomics infrastructure.
See full Stilla Technologies company page
